Chiron Corp.
Alex. Brown & Sons analyst David Webber said that Chiron Corp.'s progress with its T88 monoclonal antibody for Gram-negative sepsis has gone largely unheeded by Wall Street and therefore represents potential upside that may not be reflected in most valuation models of the stock. CHIR's progress puts it out front in the race to find a treatment for sepsis, he said.